Tel Aviv-based AI healthtech startup MDI Health has launched its end-to-end AI platform for personalized medication to solve the fourth-largest cause of world deaths, medication-related problems, the company announced Tuesday.
Follow Israel Hayom on Facebook and Twitter
MDI Health has also announced a $6 million seed round, the first results of live clinical trials in Israel, and the launch of new pilots in the US with one of the top three largest health insurers and top five largest health systems in the country.
MDI's platform provides the first full solution to adverse drug events. Not only automating CMRs so clinicians can complete them in minutes instead of hours, but also enabling them to make comprehensive and informed decisions on prescriptions based on multi-drug interactions, individual medical history, lifestyle, and other key patient-specific factors. As tested recently in clinical trials at Hadassah University Hospital in Israel, MDI Health's AI platform presented up to 40% more life-saving patient insights than the clinical pharmacists had identified.
Co-founder and CSO of MDI Healthcare Dr. Dorit Nahlieli said, "As a drug safety export, I've been trying for decades to better manage patient risk, especially when it comes to patients taking multiple medications. It is a tragedy that so many people die each year when we know CMRs are an effective solution, yet clinicians like me don't have the tools to automate such a time-consuming process and customize patient's prescriptions with the quality they deserve.
"The main solutions available focus on 1:1 interactions and adherence, leading to partial analyses, laborious processes, and a lack of standardization in terms of the outcome," she continues. "In contrast, MDI's novel AI technology enables multi-drug analyses featuring patient-specific lifestyle data to generate reliable CMRs within minutes and at scale, meaning significantly more patients get improved quality of care and lives are saved."
